News & Analysis as of

Bayer Continues To Settle Yaz/Yasmin/Ocella Cases

To date, settlements in thousands of Yaz, Yasmin and Ocella cases have been reached and it is estimated that Bayer, the drug manufacturer, has paid out over $1 Billion to more than 6,000 injured women across the country, for...more

"Third Circuit Rejects Class Without Objective Means of Identifying Members"

On August 21, 2013, the U.S. Court of Appeals for the Third Circuit reversed certification of a class action comprised of Florida purchasers of Bayer’s One-A-Day WeightSmart multivitamin. See Carrera v. Bayer Corp., No....more

Is Mirena IUD the next big Case in Reproductive Health?

Bayer Pharmaceuticals, maker of the Yaz and Yasmin birth control products as well as many other popular pharmaceuticals, is again under scrutiny with one of its top 5 grossing items, the Mirena IUD. Nearly 2 million women in...more

Serious Risks Of Yaz And Related Drospirenone Birth Control Pills Prompt Lawsuit

In 2011, the U.S. Food and Drug Administration began issuing warnings that birth control pills containing drospirenone — including brand names Yaz, Yasmin, Beyaz, Safyral and their generics Gianvi, Loryna, Ocella, Syeda and...more

News from Abroad: UK Court of Appeal Considers Sufficiency

The Court of Appeal recently heard a case relating to Genentech's patent, which claimed the use of human vascular endothelial growth factor (hVEGF) antagonists for the treatment of non-cancerous diseases which are...more

New Product Liability Class Action Highlights Uncertainties in Class Proceedings

On April 15, 2013, the Ontario Superior Court of Justice certified a product liability class action in respect of pharmaceutical products manufactured by Bayer Inc. In so doing, the Court’s reasoning highlighted the continued...more

Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. (Fed. Cir. 2013)

Contraceptives were the subject of the Federal Circuit's recent decision in Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc. But, unfortunately, it's a rather fact-specific case with nothing of prurient...more

Patent Watch: Bayer Schering Pharma AG v. Watson Pharm., Inc.

On April 16, 2013, in Bayer Schering Pharma AG v. Watson Pharm., Inc., the U.S. Court of Appeals for the Federal Circuit (Lourie,* Schall, Prost) reversed the district court's summary judgment that U.S. Reissue Patent No....more

Johns v. Bayer Corporation: Southern District of California Dismisses “Lack of Substantiation” False Advertising Class Action

In false advertising cases involving a wide range of consumer products, including dietary supplements and cosmetics, plaintiffs often allege that the manufacturer does not have adequate scientific “substantiation” for its...more

Court Report -- February 24, 2013

In This Issue: Novartis Pharmaceuticals Corp. v. Actavis LLC et al.; Precision Biosciences Inc. et al. v. Cellectis S.A. et al.; Bayer Pharma AG v. Warner Chilcott Co., LLC et al.; Promega Corp. et al. v. Life...more

A warning to US & foreign companies on Australian patent infringement by common design: Bayer Pharma AG v Genentech Inc [2012] FCA...

US and other foreign companies that do not have Australian commercial operations will be interested in this decision because it contains prima facie findings that some, perhaps, widely used commercial practices involving...more

11 Results
View per page
Page: of 1